fluzoparib + bevacizumab

fluzoparib + bevacizumab is a combination therapy consisting of fluzoparib (also known as fuzuloparib or SHR3162), an orally available small molecule inhibitor of poly(ADP-ribose) polymerase (PARP), and bevacizumab, a recombinant humanized monoclonal antibody that targets vascular endothelial growth factor (VEGF). Fluzoparib works by inhibiting PARP1 and PARP2 enzymes, which are critical for repairing single-strand DNA breaks; in cells with homologous recombination deficiency (HRD), such as those with BRCA mutations, this leads to double-strand breaks and apoptosis. Bevacizumab acts as an anti-angiogenic agent by binding to VEGF and preventing its interaction with receptors on endothelial cells, thereby inhibiting tumor vascularization. This combination is being investigated, notably in a Phase 2 study led by Chongqing University Cancer Hospital, as a maintenance treatment for patients with platinum-sensitive recurrent ovarian cancer who have previously been treated with PARP inhibitors, exploring a rechallenge strategy to overcome resistance.

Brand names

AiRuiYiAvastin

Other names

fuzuloparibfluzoparibbevacizumab